Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting

Posted on by

Preclinical data reinforce therapeutic potential of ATX-559, a first-in-class oral DHX9 inhibitor, in cancers characterized by genomic instability and replication stress Novel KIF18A inhibitor, ATX-295, selected for oral presentation discussing robust, selective activity in ovarian cancer…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.